September 2017. Reviews issues in oncology medication distribution through the specialty pharmacy provider channel. Provides SPP oncology pharmaceutical manufacturer "Partners of Choice" nominations and manufacturer ratings for account engagement and contracting.
August 2017. Examines Medicare Advantage plan approaches to oncology medication management, including strategic imperatives, utilization management, and clinical pathway activity. Provides a competitive assessment of manufacturers active in oncology and identifies opportunities for partnership.
June 2017. Reviews commercial health plan approaches to oncology management and examines the resulting market access landscape across ten cancer types.
May 2017. Examines the contracting environment and commercial health plan executive evaluations of 22 pharmaceutical manufacturers active in oncology.
October 2016. Provides an overview of the community oncology practice segment, including PDL and clinical pathway development by cancer type, manufacturer partner of choice and benchmark ratings, and the perceived reimbursement environment for 27 IV oncology medications.
October 2016. Reviews market trends, cancer centers' strategic imperatives driving decision making, and perceptions of manufacturers and the reimbursement environment across ten cancer types.
Specialty Pharmacy Provider Study: Oncology Medication Manufacturer Engagement and Contracting TrendsAs oncology leads in specialty drug spend, and roughly two-thirds of specialty drugs flow through specialty pharmacies and retail, SPPs are key to oncology medication manufacturers' channel...
As oncology medication prices rise and the market becomes more competitive, Medicare Advantage plans continue to focus on cost-effective, value-based care. HIRC's report, Medicare Advantage Study:...
The oncology market environment remains tense as medication prices continue to rise and concerns around managing the total cost of care and patient affordability accelerate. HIRC's report, Commercial...
As the oncology medication market becomes notably more competitive, manufacturers are increasing efforts to build collaborative engagements with commercial health plans. HIRC's report, Commercial...
Oncology drug costs are rising as providers transition to value-based reimbursement, leading to an increase in activity that can impact oncology medication market access. HIRC's report, Community...
As the oncology drug pipeline continues to deliver innovative and costly therapies, payers and other health care stakeholders continue to seek strategies that increase quality of care and ensure appropriate utilization. HIRC's Managed Oncology Service examines issues in oncology medication management and distribution to assist pharmaceutical firms in developing and maintaining successful market access strategies.
HIRC utilizes a triangulated research design, combining primary survey data, interview insights, and in-depth secondary research, resulting in a deep understanding of issues related to oncology medication market access.
Cancer types analyzed:
- Breast Cancer
- Colorectal Cancer
- Chronic Lymphocytic Leukemia
- Chronic Myeloid Leukemia
- Lung Cancer
- Multiple Myeloma
- Pancreatic Cancer
- Prostate Cancer
- Renal Cell Carcinoma
For more information or to subscribe, contact Raymond Co via email or at (408) 884-8560
Comprehensive Approach to Managed Markets Access
The service assesses, tracks, and benchmarks how health system stakeholders address the management and distribution of oncology medications across market segments. Commercial and Medicare Advantage health plans are examined, with a focus on strategic imperatives and developing management trends. Oncology provider segments are analyzed to assess key market issues and the reimbursement environment, and the specialty pharmacy provider (SPP) market is monitored.
- Commercial Health Plans
- Medicare Advantage Plans
- Academic and Health System-based Cancer Centers
- Community Oncology Providers
- Specialty Pharmacy Providers
Bringing Value to Subscribers
HIRC's data and insights enable subscribers to understand and track market dynamics and trends critical to optimal product positioning as the managed oncology market evolves.
Through detailed analyses, key implications, and strategic recommendations from experienced HIRC researchers, subscribers to the Managed Oncology Service are able to identify potential opportunities for partnerships and evaluate account management strategies to effectively support the oncology-specific needs of managed care.